MegaZone Cloud (CEO Donghoon Yeom), an AI and cloud company, has signed a strategic partnership with biotech company CellKey AI to develop next-generation bio AI solutions globally. The signing ceremony took place at the MegaZone Industry-Academia-Research Center in Gwacheon, Gyeonggi Province, and was attended by key representatives from both companies.
Through this collaboration, MegaZone Cloud will provide cloud and AI infrastructure, while Cellkey.AI will operate its bio-vertical AI agent, "BioEOS," within this infrastructure environment, promoting global market expansion. The two companies plan to expand their collaboration with pharmaceutical and biotech companies and hospitals, focusing on operational optimization, technological advancement, implementation consulting, proof-of-concept (PoC), and operational support for BioEOS.
“Considering the scale and complexity of data in the bio industry, the combination of stable cloud infrastructure and AI analysis capabilities is essential,” said Yeom Dong-hoon, CEO of MegaZone Cloud. “By combining Cellkey.AI’s platform and MegaZone Cloud’s infrastructure, we will create tangible results in the pharmaceutical, bio, and medical fields.”
“BioEOS is a solution that analyzes and automates bio data and workflows based on AI to support research and development decision-making,” said Lee Nam-yong, CEO of Cellkey AI. “Through this collaboration, we plan to strengthen security and operational stability and present competitive bio AI solutions in global markets such as Japan.”
MegaZone Cloud, with over 2,000 cloud and AI experts, supports the digital transformation of over 8,000 domestic and international clients and operates local subsidiaries in 10 countries, including North America, Japan, Southeast Asia, and Oceania. Founded in 2019, Cellkey AI is a bio-AI company specializing in new drug development, precision medicine, and AI-based diagnostics, providing customized AI solutions for the bio industry.
- See more related articles
You must be logged in to post a comment.